People · Operator
Named in public records as an officer, director or promoter · active 2015–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arcellx, Inc. | — | Biotechnology | Series D+ | $272.8M | $1.8B | 2019 |
| AirNexis Therapeutics, Inc. | — | Biotechnology | Series C | $62.0M | $309.0M | 2026 |
| Nkarta, Inc. | — | Biotechnology | Series C | $43.9M | $1.8B | 2019 |
| Vasculox, Inc. | — | Pharmaceuticals | Series B | $42.6M | $1.1B | 2015 |
Jill Carroll at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jill Carroll on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 2 | 17 |
| Tiba Aynechi | 2 | 9 |
| Charles Bolten | 1 | 10 |
| Fouad Azzam | 1 | 8 |
| Dan Broderick | 1 | 7 |
| MICHAEL DYBBS | 1 | 5 |
| Lewis T. Williams | 1 | 5 |
| Bobby W. Sandage, Jr. | 1 | 5 |
| Robert W. Karr | 1 | 4 |
| Derek Yoon | 1 | 4 |
| Maria Fardis | 1 | 3 |
| Colin Walsh | 1 | 3 |
| Anna Chen | 1 | 3 |
| David Lubner | 1 | 3 |
| Evan Caplan | 1 | 2 |
| Roger Sawhney | 1 | 2 |
| Peter T. Moldt | 1 | 2 |
| Carole L. Nuechterlein | 1 | 2 |
| Kavita Patel | 1 | 2 |
| Lance Thibault | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.